PTPRC and neoplasm: Lymphocytes were gated on human CD45+ cells and histograms depicting CD38 expression between the two treatment conditions clearly demonstrate a significant decrease in CD38 expression in the residual tumor cells exposed to αCD38 antibody, whereas those in the IgG isotype condition retained their robust CD38 expression (Fig. 2C).